Afriag Share Discussion Threads

[longrod] 15/7/2019 16:25

£1m in an extremely difficult market seems to disagree with your particular pathological position PR100

Seems a bit personal to me.

Going to be funny watching you fumble your way through the next few months.

[cpap man] 25/6/2019 12:06

#AFRI

NEX:AFRI #AFRI

Like the article in the Mail on Sunday reference #AFRI moving to AIM, LSE [standard] list or failing that NASDAQ or the TSXv in Canada

As soon as that is done then for sure #AFRI will go whoosh!!!!

😎



David Lenigas
@DavidLenigas
Following Following @DavidLenigas
More
I managed to pick up 17 million AfriAg yesterday out of the 62 million traded. I can smell this one as a very good one. I want to be part of Dr Barnhill’s cancer cure efforts. AfriAg Global Plc: Director/PDMR Shareholding ⁦@AfriAgPLC297; …

[longrod] 23/6/2019 21:25

Ive invested as well!!

Just got to know when to sell with Lenogas.

The guy is a front end expert, however i also agree with PR100 you do have to get off before it all collapses but this hasn't even started yet, at .1 of a penny in my mind its all upside from here. Fingers crossed.

[pr100] 23/6/2019 14:03

I've seen that video - and everything else out there. With respect, it doesn't prove that Dr Barnhill is honest albeit I have not suggested otherwise. Nor does it show the current state of the facility: the B-roll footage is years old and some of it may not even have been shot in Negril.

So, I'll try again. Do you know of any images of the current state of this facility? Or any published reports of the investment or progress on site? And who owns what? It's not enough to claim that you have seen the evidence, as I'm sure you can understand.

And why use tiny Vimeo for promotional videos. What's wrong with YouTube?

Incidentally, it's perfectly possible to list a compliant medical cannabis firm on LSE or AIM, as some have done. But you do have to prove that what you're doing is legal under UK law - and risk not finding it easy to raise cash from UK institutions.

[pr100] 23/6/2019 12:59

Well, I seem to be talking to you at least, sammy.

You obviously don't know much about Afriag or Lenigas. The former is skint and wouldn't be able to list anywhere; and the latter is rich (because his shareholders have been asset-stripped) and knows full well that he is again talking hot air in another attempt to ramp up Afriag's pathetic share price so that he can raise another handful of shekels.

Even when Afriag wasn't smoking weed, they couldn't get off the NEX lobster pot so the chances that they can list elsewhere now are somewhere between slim and none - with slim having left town long ago.

But if you really do know Apollon, you're very welcome. Maybe you could link me to some photographs of the redeveloped Negril Doc's Place? It's about to re-open right? Even though it's impossible to book.

And maybe you know how much of Apollon Formularies Jamaica Ltd (AFJL)is actually owned by the Apollon Formularies Ltd (AFL), the one-man UK shell owned and operated by Aussie, Rod McIllree? The Afriag RNS's aren't clear.

And why have there been no local news reports of this big redevelopment of the former failed weed bar and restaurant? Do you know the name of the firm which carried out the work? Did Apollon issue any news reports/updates about progress on site? Do their accounts show this capital expenditure? Did the 51% owner also contribute? Who is the 51% owner?

To me, this has got scam written all over it; but if you know different please post some evidence and I will be glad to change my view.

As for Doc's Place, it's presumably a franchise. So in the unlikely event that Apollon were to exercise their alleged right to buy it, they would only be buying the franchise right? Would that come with ongoing liabilities to the franchise owner in the US?

But you're right: I have zero faith in Lenigas. His public companies never make a profit so shareholders never get any return for the long term pain they suffer from constant dilution. Even his own brother accuses him of being a money-laundering scammer intent only on enriching himself:


Nice to meet you though.

[pr100] 04/6/2019 09:51

He, personally, has one job and it is not running a successful business, as he has admitted. All he does is raise cash and he flits from bubble to bubble to make it easier. Of course, he leaves a trail of write downs and skint PIs in his wake but he doesn't give a fig.

One day, a forensic accountant will reveal what Lenigas personally earns from each fundraise he arranges. But it will be a convoluted trail.

Some of the deals he does with startup/deadwood/zero assets/one-man investees for millions of dollars should also be investigated. There is never any proof that the cash ends up where it is supposed to - and even less proof that it ever builds a viable business.

Investees and PIs go bust by the bucketload but Lenigas always prospers, judging by the portfolio of real estate he owns around the world. That's his real "global focus".

[apfindley] 04/6/2019 08:43

All this company and lenigas seem to do is jump from one latest in vogue sector to another, year after year....and then change the name to suit the supposed renewed business focus

[aidenabettin] 04/6/2019 04:04

Working with his mate Chris Cleverly?.hTTps://www.sharecast.com/news/aim-bulletin/afriag-seeks-to-become-vertically-integrated-cannabis-firm-through-appolon-investment--3932510.html.hTTp://www.stockmarketwire.com/article/6445754/Block-Commodities-appoints-DAmbrosio-as-chief-medical-officer.html

[pr100] 01/6/2019 11:04

In case David Lenigas is about to dispose of Afriag Global Plc's assets (or write them off), shareholders should hold the company to account for its significant alleged investment in Afriag (Pty) Ltd and its associate companies.

There can be no doubt, for example, that AFRI owned 40% of then associate, Amalgamated Tobacco Manufacturing (ATM). Notwithstanding the fact that ATM's assets were subsequently transferred to another company owned by Paul de Robillard, AFRI's share of it will still need to be accounted for in the final analysis.

Also, there has been no formal filing by Afriag (Pty) Ltd which declares the 40% equity interest owned by AFRI so shareholders may find their interests obstructed by legal challenges when AFRI's assets in South Africa are disposed of.

In email conversations with me ("The Lenigas Emails"), apparently monitored by his lawyers, Lenigas tried to claim, untruthfully, that neither he nor AFRI had ever had any involvement with ATM - but the evidence shows otherwise.

As AFRI may now be about to declare disposals or write-offs for all its southern African agri-logistics assets, shareholders need to know whether they are being treated fairly. To that end, I urge you to read or re-read The Lenigas Emails and seek legal advice before the assets disappear. You'll find them here - and of course, the original documents are unredacted:



or

[pr100] 30/5/2019 14:32

I hope some of you managed to bail out.

[cpap man] 24/5/2019 19:38

24 May 2019

AfriAg Global PLC

('AfriAg' or the 'Company')

GBP1 million Placing

and

Intention to commence investment into Jamaican focused medicinal cannabis
pharmaceutical company

AfriAg Global PLC, a company whose shares are admitted to trading on London's
NEX Exchange, is pleased to announce that, further to its news release dated 16
May 2019, the Company has raised a total of GBP1,000,000 before expenses.

300 million new ordinary shares in the Company have been placed (the
"Subscription Shares") at a price of 0.10 pence per Subscription Share (the
"Subscription Price") to a number of placees (the "Subscription") raising GBP
300,000, before expenses. This Subscription is conditional only upon admission
of the Subscription Shares to trading on NEX Exchange ("Admission").
Application will be made for the Subscription Shares to be admitted to trading
on NEX and it is anticipated that Admission will occur on or about 30 May 2019.

In addition, the Company has conditionally placed a further 700 million new
ordinary shares in the Company (the "Conditional Shares") at a price of 0.1
pence per Conditional Share (the "Conditional Price") to a number of placees
(the "Conditional Subscription") raising GBP700,000. Completion of the
Conditional Subscription is subject to shareholder approval of certain
resolutions to authorise the issue and allotment of the Conditional Shares at a
general meeting to be held on 19 June 2019 and conditional on admission to
these Conditional Shares to trading on NEX Exchange ("Conditional Shares
Admission"). The circular and notice of a general meeting of the Company to be
held on 19 June 2019 ("General Meeting") to, inter alia, pass the resolutions
required to authorise the directors of the Company to be able to issue and
allot ordinary shares in order to fund the Company's ability to complete the
Investments, is expected to be published shortly. Following its publication,
the circular will be available on the Company's website at hxxps://
www.afriagglobal.com.

As previously announced, the Company has entered into a conditional
subscription agreement with Apollon Formularies Ltd ("Apollon") and has
subscribed for (1) for 1.2 million shares in Apollon at a price per share of GBP
0.25 representing approximately 0.71 per cent. of Apollon's issued share
capital for an aggregate investment amount of GBP300,000, subject to completing
the Subscription; and (2) 2.8 million shares at a price per share of GBP0.25
representing approximately 1.63 per cent. of Apollon's issued share capital for
an aggregate investment amount of GBP700,000, which investment is subject to
receiving shareholder approval at the General Meeting (the "Investments").

Transaction History:

On 16 May 2019, the Company announced it had agreed with Apollon, a UK
incorporated company, to subscribe for shares in Apollon in a conditional
multi-stage investment transaction (the "Investments").

The Company also advised on 16 May 2019 that is in discussions with the
shareholders of Apollon to be granted right of first refusal to acquire all the
issued and outstanding shares owned by those shareholders in consideration for
the issue and allotment to those shareholders of new ordinary shares in the
capital of the Company at a price of 0.1 pence per new ordinary share ("Right
of First Refusal") which values the transaction at circa GBP40,000,000.

Following exercise of the Right of First Refusal, which will be subject to
approvals from (as applicable) (1) all the necessary government authorities,
including the cannabis licencing authority (in Jamaica); (2) regulatory
authorities; (3) approvals from the Company's shareholders; and (4) approvals
from the shareholders of Apollon, the existing shareholders of Apollon will
hold circa 93.54 per cent. of the issued share capital of the Company.
Following completion of the Investments and should the Company exercise the
Right of First Refusal, the resulting enlarged group will be a vertically
integrated medicinal cannabis group with operations in Jamaica and with plans
to expand elsewhere throughout the world.

David Lenigas, Executive Chairman of AfriAg Global PLC, commented;

"I'm please to close this Stage 1 Placing of GBP300,000. When these proceeds are
cleared, the first GBP300,000 proposed investment in to Apollon will be targeted
towards opening Apollon's first revenue generation businesses at Doc's Place
Wellness Center and Apollon's first dispensary and processing facility in
Negril, Jamaica and will secure the option to acquire 660 acres of prime
agricultural land for future cultivation expansion.

AfriAg is one of the very few companies in the UK and indeed Europe that is
capable of doing a transaction of this type in the legal medicinal cannabis
sector. Once the Right of First Refusal is agreed and exercised, we will be the
first listed company in the UK to be a fully integrated medical cannabis
pharmaceutical company.

Subject to the Right of First Refusal being agreed and entered into, the
exercise of the Right of First Refusal may constitute a reverse takeover under
Rule 57 of the NEX Rules."

Business overview of Apollon and its assets:

Apollon, an international medicinal cannabis pharmaceutical company,
principally conducts business through Apollon Formularies Jamaica Limited ("AFJ
"), which is a government licensed medicinal cannabis company located in
Jamaica. Apollon, both directly and through its subsidiaries and affiliates
such as AFJ, has developed a suite of proprietary, trade secret, medical
cannabis strains, technology, pharmaceutical products and therapeutic
applications and AFJ is licensed and approved to cultivate, process,
manufacture, perform research and develop, sell and distribute within the
legalized hemp and medical cannabis industry in Jamaica.

AFJ is licensed and approved to operate on the national (Federal) level in
Jamaica via the following licenses and approvals: Retail (Therapeutic) License,
Processing License, and Cultivation Conditional Approval pending final
inspection of the cultivation facility all issued by the Cannabis Licensing
Authority (CLA). AFJ has also received an approval Order for Cultivation and
Clinical Trials. Together, these licenses and approvals allow for the
cultivation, processing, manufacture, research and development, and retail
sales of medical cannabis pharmaceuticals in Jamaica and, export
internationally when the forthcoming regulations are finalized by the Jamaican
government which is expected in the near future. It is expected that these
regulations will allow legal export from CLA Licensed companies in Jamaica to
any country where Apollon has purchase agreements and the laws of that country
allow import of medical cannabis pharmaceutical products.

Along with patient care and its research and development programme, Apollon,
both directly and through subsidiaries and affiliates such as AFJ, has created
and obtained proprietary hybrid medical cannabis pharmaceutical strains,
technology, formulations, and treatment products. Many of these formulations
were created using Apollon's proprietary artificial intelligence techniques and
include:

* Apollon NAUSEAT

* Apollon PAINT

* Apollon SLEEPT

* Apollon ANTI-INFLAMMATORYT

* Apollon SEIZUREST

* Apollon APPETITET

* Apollon CANCERT(APMT) - High Times Cannabis Cup 1st Place Winner.

The patient treatment side of AFJ's business is accomplished through physician
managed clinical treatment wellness resorts and retail locations within
Jamaica. In particular, AFJ has an arrangement with Doc's Place International,
Inc. ("Doc's Place"), which operates the Global Centre of Excellence for
Medical Cannabis Therapy in Negril, Jamaica. Doc's Place is an in-patient and
out-patient medical cannabis wellness resort, which is used by international
and Jamaican patients needing access to licensed physicians with specific
expertise in medical cannabis treatment and to be prescribed medical cannabis
products as has been legalised in Jamaica since April, 2015. This wellness
centre is located in Negril, on the western side of Jamaica and currently has 5
in-patient treatment rooms and additional accommodations for circa 100
out-patients, with plans to expand to an 80 to 100 room in-patient treatment
resort with additional accommodations for circa 500 out-patients via the
purchase or rental of a second ocean front wellness resort. Any licensed
physician in Jamaica, including the physicians working at Doc's Place, can
write prescriptions for AFJ's medical cannabis pharmaceuticals.

The current research-driven areas of AFJ are focused upon the following:

1. Physician supervised clinical trials for patient outcomes validation,

2. Accurately determined appropriate disease and patient specific formulations
created using Apollon's State-of-the-Art proprietary artificial
intelligence techniques,

3. Quality dose controlled medical cannabis oil production,

4. Quality controlled legal growth of medical cannabis strains,

5. Extraction methodology, distillation, cannabinoid isolation, purification
and pharmaceutical manufacturing.

6. Consistent dosing globally and legally through Apollon's delivery systems
including one of the world's first medical cannabis 3D printer capable of
precise manufacturing of Apollon's dose - controlled pharmaceutical
formulations internationally , and

7. Global brand recognition per a consolidated strategy combined with
proprietary medical cannabis strains and products.

AFJ's business objectives include the following items being accomplished in the
near future:

1. Produce commercial volumes of high-grade, full-strength medical cannabis
oil that will be processed at its large scale federally legal processing
facility. This facility has State-of-the-Art laboratory extraction
equipment with a current capacity of producing approximately 15,000 grams
of the highest quality medical cannabis oil per day for retail sales in
Jamaica and export to all countries where legal import is allowed. Medical
cannabis oil is the primary ingredient for medical cannabis based
pharmaceuticals, nutraceuticals, cosmeceuticals, foods and beverages.

2. Initially cultivate Apollon medical cannabis strains in its current
greenhouse facility and expand to a 660 acre farm to be acquired or leased.
The Company understands this will allow AFJ to grow approximately 1600
pounds of medical cannabis flower per acre per year.As an additional source
of revenue, AFJ has established a medical cannabis collective pursuant to
which it intends to allow local Jamaican farmers and other international
companies to lease portions of its farm to grow medical cannabis strains on
a cost plus 20% basis grown through Apollon's farming infrastructure and
utilizing AFJ's licences.

3. Own and operate multiple medical wellness resorts, Doc's Place facilities,
and retail locations throughout Jamaica offering Apollon's clinical trial
tested, pharmaceutical products as produced by AFJ including award-winning
Apollon CancerT used to treat cancer patients.

4. Establish and maintain a global market position.

Apollon Formularies Jamaica, Limited

Apollon holds an indirect 49% interest in the issued share capital of AFJ, a
limited corporation existing under the laws of Jamaica, through an arrangement
with Dr. Stephen D. Barnhill and is entitled to 95% of the net profit of the
business of AFJ. Apollon has entered into an agreement with Dr Barnhill
pursuant to which Dr Barnhill has agreed to assign his 49% interest (the
maximum allowed under Jamaican law) of the stock in AFJ to Apollon immediately
on approval of the assignment by the Cannabis Licensing Authority (CLA). In
addition to such interests and rights as described above, AFJ currently has
several asset purchase agreements and strategic partnerships in place to fulfil
the mission of creating an all-encompassing, worldwide medical cannabis
corporation that can satisfy the growing global market for legal, medical
cannabis pharmaceuticals.

Doc's Place International, Inc.

Apollon has an exclusive right to acquire 90% of the stock of Doc's Place, a
corporation organized and existing in the State of Georgia, USA, which includes
its Wellness Center, the Global Centre of Excellence for Medical Cannabis
Therapy located in Negril, Jamaica. In addition to such interest and right,
there exists a leasing arrangement between AFJ and Doc's Place for AFJ to be
the exclusive cannabis retail location and treatment operation located on the
premises.

CBev Ventures, Inc.

Apollon also has an exclusive right to purchase the assets of CBev Ventures,
Inc., a corporation organized and existing in the State of Georgia, USA
("CBev"), a beverage company that develops, markets, distributes and sells
functional and craft beverages in the legal hemp and medical cannabis industry.

Roxy Industries Ltd.

Following the acquisition of CBev, Apollon will hold through CBev an exclusive
right to purchase the assets of Roxy Industries Ltd., a Jamaican company that
bottles, cans, and packages beverages for its customers.

Proposed Transaction Overview:

* The Company to subscribe for 1.2 million shares in Apollon at GBP0.25 per
share representing 0.71 per cent. of Apollon's issued share capital for an
aggregate investment amount of GBP300,000, conditional on being able to raise
the required funding;

* The Company to subscribe for a further 2.8 million shares in Apollon at a GBP
0.25 per share representing 1.63 per cent. of Apollon issued share capital
for an aggregate investment amount of GBP700,000, conditional upon the
resolutions at the General Meeting being passed and being able to raise the
required funding;

· The Company is in discussions with the shareholders of Apollon to be
granted the Right of First Refusal to acquire all the issued and
outstanding shares owned by those shareholder in consideration for the
issue and allotment to those shareholders of new ordinary shares in the
capital of the Company at a price of 0.1 pence per new ordinary share which
values the transaction at circa GBP40,000,000. Following exercise of the
Right of First Refusal, which will be subject to all the necessary
regulatory and shareholder approvals, the existing shareholders of Apollon
will hold circa 93.54 per cent. of the issued share capital of the Company.

* Subject to the Right of First Refusal being exercised:

* The Company may add senior Apollon officials and representatives to the
board of the Company.

+ The Company constitute a board of advisors, which will comprise of
certain members of the Company's management along with other
scientists, physicians and business executives including Dr. Anthony
Hall, a US Board Certified Neurosurgeon with special expertise in
medical cannabis pharmaceuticals, to join as Chief Medical Officer of
the Company

Key Apollon Individuals

About Dr. Stephen Barnhill (Proposed Chairman and Managing Director of the
Company, subject to the Right of First Refusal being exercised)

Dr. Stephen D. Barnhill is a physician, Fellowship trained in Laboratory
Medicine and Board Certified by the American Board of Bioanalysis. Dr. Barnhill
is currently Chairman and CEO of Doc's Place International, Inc., the first
Global Centre of Excellence for Medical Cannabis Therapy in Negril, Jamaica, as
well as, Chairman and CEO Apollon Formularies, Inc., a U.S. affiliate of
Apollon Formularies Jamaica, Limited to which he also serves as President and
Board Member.

Dr. Barnhill has been a founder, Chairman and CEO of both private and public
companies. He was most recently founder, Chairman and CEO of a U.S. publicly
traded international biotech company, which he took from inception to
profitability. In addition, he was founder, Chairman and CEO of BCL
laboratories, LLC with operations in south-eastern U.S. which was acquired by
Corning-MetPath, now Quest Diagnostics, the largest clinical laboratory in the
world. Dr. Barnhill served as a Medical Director for Quest Diagnostics for
approximately 5 years after the acquisition. Dr. Barnhill was also founder,
Chairman and CEO of National Medical Specialty Labs, which was acquired by
Horus Therapeutics Inc., a New York based pharmaceutical company. Dr. Barnhill
served as President of Horus Therapeutics for several years after the
acquisition. Dr. Barnhill is a pioneer in artificial intelligence machine
learning (pattern recognition algorithms) and an inventor on more than 40
patents including neural networks and support vector machines ("SVM") including
the Hallmark SVM-RFE technique now cited by more than 10,000 publications. His
patents were part of the intellectual property portfolio that won 1st Place out
of 1600 publicly traded companies and was awarded the MICO award from MDB
Capital for the most disruptive intellectual property portfolio. Dr. Barnhill's
neural network patents were acquired by Johnson & Johnson. He is also an
inventor on patents related to laboratory developed tests and tumour markers.
His work includes expertise in the clinical laboratory involving clinical
chemistry, haematology, microbiology, blood banking, toxicology and immunology,
as well as diagnostic test development relating to cancers of the prostate,
pancreas, breast and ovary, cytogenetics, flow cytometry, FISH and imaging in
digital mammography, and funduscopic analysis of macular degeneration (AMD). He
was part of the team that launched the first iPhone app using SVM for melanoma
detection. Dr. Barnhill has negotiated and executed deals with many companies,
including Pfizer, Corning-Metpath, Quest Diagnostics, Clarient (now GE
Healthcare), LabCorp, NeoGenomics, Abbot, Bruker and others. He has published
many peer reviewed papers with academics including those from MD Anderson
Cancer Centre, Johns Hopkins University Medical Centre, Stanford University
Medical Centre and others. He is a frequently invited speaker to medical
conferences in the US and internationally. He has raised millions of dollars in
start-up and ongoing financing for both private and public companies.

Dr. Barnhill is or has been a Member or Fellow of the American College of
Physician Inventors, the American College of International Physicians, the
American Medical Association, the American College of Physician Executives, the
American Association of Artificial Intelligence, the American College of
Managed Care Medicine, the Association of Clinical Scientists, the American
Society of Contemporary Medicine and Surgery, the American Society of Law,
Medicine and Ethics, the Southern Medical Society, the American Federation for
Clinical Research, the National Federation of Catholic Physicians and the
Society of Cannabis Clinicians.

About Dr. Herb Fritsche

Herb Fritsche, Ph.D. is a world-renowned Clinical Chemist and was Professor of
Laboratory Medicine and Chief of the Clinical Chemistry Section at The
University of Texas, M.D. Anderson Cancer Centre in Houston, Texas. During his
41 years at M.D. Anderson Cancer Centre, Dr. Fritsche focused his research
activities on the development and validation of cancer diagnostics. Dr.
Fritsche has participated in the validation and FDA clearance process for every
commercial serum tumour marker product currently in use in the United States.

Dr. Fritsche has served as President of the Clinical Ligand Assay Society
(CLAS) and on many various national committees for both the CLAS and the
American Association for Clinical Chemistry (AACC). He is a Fellow of the
National Academy of Clinical Biochemistry and was awarded the National Award
for Contributions in Education by the AACC; the Outstanding Clinical Chemist
Award by the Texas Section, AACC; a Dean's Excellence Award from the University
of Texas Graduate School of Biomedical Science; a Distinguished Scientist Award
from the CLAS; the Johnson and Johnson Award for Outstanding Research and
Contributions to Clinical Biochemistry from the National Academy of Clinical
Biochemistry; the Morton K Schwartz Award for Outstanding Achievements in the
field of Cancer Diagnostics from AACC; the Carl Jolliff Award for Lifetime
Achievements in Immunology and Immunodiagnostics from the Immunology Division
of the AACC; and most recently, the Morton K Schwartz for significant
contributions to the development of cancer diagnostics from the New York Metro
Division of the AACC. Dr. Fritsche served on the Expert Panel for developing
Tumour Marker Practice Guidelines for the American Society of Clinical Oncology
(ASCO) from its inception until his retirement, and he currently serves on the
Laboratory Practice Guidelines Committee for the National Academy of Clinical
Biochemistry. In addition, he serves on the Editorial Board of six
international scientific journals. Dr. Fritsche is a consultant/advisor to the
National Cancer Institute and for some major international diagnostic companies
and biotech start-up companies. Dr. Fritsche has published over 200 peer
reviewed scientific papers, invited articles and book chapters. He holds 3
patents. He has lectured extensively for many years at international and
national meetings of medical and professional societies, and he is recognized
internationally as an expert in the field of clinical chemistry, cancer
diagnostics and laboratory medicine.

Notice Regarding Forward-Looking Statements

This announcement includes "forward-looking statements" involving the Company,
the other entities referenced in this announcement, and the respective
subsidiaries, affiliates and associates of the Company and such other entities
(collective, the "Involved Entities"), which include all statements other than
statements of historical facts, including, without limitation, those regarding
the financial position, business strategy, plans and objectives of management
for future operations, and any statements preceded by, followed by or that
include forward-looking terminology such as the words "targets", "believes",
"estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates",
"would", "should", "could" or similar expressions or the negative thereof. Such
forward-looking statements involve known and unknown risks, uncertainties and
other important factors beyond the control of the Involved Entities that could
cause the actual results, performance or achievements of the Involved Entities
to be materially different from future results, performance or achievements
expressed or implied by such forward-looking statements. Such forward-looking
statements are based on numerous assumptions regarding the present and future
business strategies of the Involved Entities and the environment in which the
Involved Entities will operate in the future. These forward-looking statements
speak only as of the date of this announcement. The Company, on behalf of
itself and each of the Involved Entities, expressly disclaims any obligation or
undertaking to disseminate any updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in expectations
of any Involved Entities with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result
of these factors, readers are cautioned not to rely on any forward-looking
statement.

The directors of the Company accept responsibility for the contents of this
announcement.

-ENDS-

For further information on AfriAg Global please visit the www.afriagglobal.com
or please contact;

AfriAg Global Plc:


David Lenigas (Executive Chairman)
[phone]

Peterhouse Capital Limited
[phone]

Guy Miller/Fungai Ndoro

[apfindley] 21/5/2019 15:52

Yes he wants to issue more billions of shares.Same with kadence today.Its likes hes crawled out from under his rock to pump both companies on the same day.

[pr100] 21/5/2019 12:18

Funny to see Lenigas pretending to be impressed with the increased level of interest in AFRI shares when it is clearly him or his advisors/associates doing the trading in order to force the share price above the par value of 0.1p.

The clue is in the last RNS:

"Pursuant to the Investments the Company would need to raise approximately £1m to subscribe for a total of 4.0 million shares in Apollon, representing circa 2.325 per cent. of Apollon’s issued share capital. The Company is considering all options in relation to the fundraise.
[b]It should be noted that the par value of the Company’s ordinary shares are 0.1 pence per share.[/b]"

Without a consolidation, they would have been prohibited from issuing new finance equity at the former sub-0.1p share price

Good opportunity to bale out as this manipulation looks highly temporary - even without the massive dilution which obviously looms.

[jimb2] 20/5/2019 16:00

pr100

brings back memories of RSH

[pr100] 17/5/2019 08:32

The formula:

1. List on a tiny lobster pot exchange where any attempt to sell £1k-worth of shares causes a meltdown.

2. Issue confetti until the share price is so low no-one can afford to sell.

3. Consolidate the shares so that more confetti can be issued.

4. Buy into worthless associates at a ridiculous premium to their true worth - selling existing assets at a knockdown price in order to do so.

5. Pump like crazy to pretend that the worthless associates will have a value one day.

6. Issue more confetti and pump.

7. Donate or "lend" scarce cash to worthless associates so that PIs will never see it again.

8. Issue more confetti and pump.

9. Remunerate the chairman obscenely for robbing PIs blind.

10. Issue more confetti and pump.